查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1918189

去礦骨基質市場－2026-2031年預測

Demineralized Bone Matrix Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計脫礦骨基質市場將從 2025 年的 12.24 億美元成長到 2031 年的 16.38 億美元，複合年成長率為 4.98%。

脫礦骨基質（DBM）市場在更廣泛的骨生物製藥和移植骨替代物產業中佔據著重要的細分市場。 DBM是一種同種異體移植材料，由人類骨加工而成，去除了礦物質成分，但保留了其骨誘導蛋白和膠原蛋白結構。它在骨重組中用作骨缺損填充材和生物增強劑，佔據了純粹的骨傳導性合成材料和更複雜的細胞骨移植材料之間的重要市場地位。

核心產品特性與臨床證據

脫鈣骨基質（DBM）的主要價值在於其骨誘導潛能，即誘導宿主幹細胞分化為具有成骨潛能的成骨細胞的能力。這種生物活性源自於其保留的骨形成蛋白（BMP）和生長因子，使其有別於惰性骨移植替代材料。其脫礦質且柔韌的特性使其能夠適應複雜的骨缺損形狀。在臨床上，DBM被用作多種手術中的移植填充物或增強劑，尤其是在脊椎融合手術、骨折不癒合以及牙科和顱顎顏面重組中，它在促進自然癒合過程中發揮著重要作用。

主要市場成長促進因素

推動市場擴張的一個重要人口因素是全球人口老化。老年人罹患骨質疏鬆症、退化性關節疾病和脆性骨折的比例較高，這些疾病都會導致整形外科手術和脊椎融合手術數量的增加。這種老化趨勢將導致需要骨移植解決方案以實現骨癒合的患者群體持續成長，從而推動對脫鈣骨基質（DBM）作為生物補充劑的穩定需求。

同時，骨骼相關疾病和損傷的發生率不斷上升，以及患者對功能恢復的期望日益提高，都推動了外科手術數量的成長。諸如脊髓退化、骨折不癒合以及創傷或腫瘤切除後嚴重的骨缺損等疾病，需要使用能夠積極促進癒合的植入材料，這就支持了骨誘導劑（例如脫鈣骨基質）的應用。

該領域的技術和工藝進步是推動成長的關鍵因素。創新主要集中在提高脫鈣骨基質（DBM）產品的一致性、生物活性和操作特性。這包括改進供體篩檢、增強加工技術以維持生長因子的功效，以及開發專用載體配方（例如凝膠、糊劑、條帶），從而方便外科醫生使用並確保產品在手術部位的保留。將DBM與合成支架和其他生物製藥結合，以製備最佳化的複合移植物，也是未來發展的重要促進因素。

DBM的市場地位得益於其在醫院環境中持續高水平的手術量，尤其是在脊椎融合手術和複雜整形外科翻修手術領域。醫院之所以成為這些手術的中心場所，是因為其擁有完善的手術通訊協定、輔助技術（例如影像、導航）以及與高成本的替代方案相比，基於同種異體移植的手術通常享有更優惠的報銷途徑。

主要應用領域：脊柱和牙科

兩個應用領域特別突出：脊椎融合手術是其核心市場，脫鈣骨基質（DBM）被廣泛用作自體骨增強或替代材料，以促進後外側融合術和椎間融合術中的關節融合。 DBM已融入退化性脊椎疾病的標準手術流程，這為其臨床應用提供了支持。

牙科是脫鈣骨基質（DBM）的另一個主要且快速成長的應用領域。在口腔顎顏面外科中，DBM用於齒槽嵴保存術（為植入做準備）、拔牙後的齒槽窩移植以及鼻竇增高術術。其促進這些部位高品質骨再生的生物學特性備受重視，且易於使用，使其成為牙科手術的理想選擇。

區域趨勢

北美在脫鈣骨基質（DBM）市場保持主導地位。這項優勢歸功於該地區擇期整形外科和脊椎手術數量龐大、組織庫和同種異體移植處理基礎設施完善、報銷政策優惠，以及外科醫生對先進生物材料的早期應用。該地區先進的醫療保健生態系統為供需雙方提供了支援。

亞太地區被公認為高成長市場，具有巨大的擴張潛力。這主要得益於醫療基礎設施的改善、醫療旅遊業的蓬勃發展、先進外科技術的日益普及以及人口大國醫療支出的成長。各國政府為推動醫療設備監管現代化和吸引外資所做的努力，也進一步促進了該地區的市場發展和本地製造能力的提升。

競爭格局與策略重點

競爭環境包括專業的骨生物製藥公司、設有生物製藥部門的大型整形外科器械製造商、組織處理機構。競爭對手專注於產品系列的廣度、骨誘導性的穩定性、載體技術，並透過專業的銷售和醫學教育團隊與外科醫生建立牢固的關係。

公司策略重點在於透過獨特的加工方法、組合產品（例如，添加幹細胞或合成顆粒的脫鈣骨基質）以及獲取臨床數據來支持其促進骨骼癒合的功效，從而實現產品差異化。此外，公司也正在投資最佳化從組織捐贈到成品分銷的供應鏈，以確保可靠性和規模化。

未來市場趨勢

脫鈣骨基質（DBM）市場的未來發展方向將著重於產品的進一步最佳化和實證應用。持續的研究將有助於更精確地量化和標準化不同DBM製劑的骨誘導潛能，從而實現更可預測的性能。遞送系統和組合產品的創新將解決在複雜手術部位的操作和保留難題。

骨移植替代材料的市場競爭格局也對其產生影響，其中包括合成替代材料和其他先進的生物製劑。脫鈣骨基質（DBM）的地位將取決於其能否繼續在複雜的骨癒合過程中發揮基礎構建模組的作用，同時在常規手術中展現出經濟高效的生物增強效果。作為一種成熟的主流生物材料，DBM有望實現穩定成長，這得益於人口結構的變化趨勢以及其在整形外科、脊椎外科和牙科等骨缺損外科治療中的重要作用。

本報告的主要優勢：

  • 深入分析：提供對主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、行業垂直領域和其他細分市場。
  • 競爭格局：了解全球主要參與者的策略舉措，並了解透過正確的策略進入市場的機會。
  • 市場促進因素與未來趨勢：探索推動市場的動態因素和關鍵趨勢及其對未來市場發展的影響。
  • 可操作的建議：利用這些見解，在動態環境中製定策略決策，發展新的業務流和收入來源。
  • 受眾廣泛：適用於Start-Ups、研究機構、顧問公司、中小企業和大型企業，且經濟實惠。

它是用來做什麼的？

產業與市場分析、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法規結構及影響、新產品開發、競爭情報

報告範圍：

  • 2021年至2025年的歷史數據和2026年至2031年的預測數據
  • 成長機會、挑戰、供應鏈前景、法規結構與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 按業務板塊和地區（包括國家）分類的收入和預測評估
  • 公司概況（策略、產品、財務資訊、關鍵發展等）

目錄

第1章執行摘要

第2章 市場概覽

  • 市場概覽
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 商業情境

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策與法規
  • 策略建議

第4章 技術展望

5. 脫礦骨基質市場（依產品分類）

  • 介紹
  • 凝膠
  • 油灰
  • 貼上
  • 移植材料
  • 其他

6. 按材料分類的脫礦骨基質市場

  • 介紹
  • 人類骨基質
  • 動物源性骨基質
  • 合成DBM

7. 按應用分類的去礦骨基質市場

  • 介紹
  • 脊椎融合手術
  • 牙科/顎顏面外科
  • 創傷外科
  • 關節重組
  • 其他

8. 依最終用戶分類的去礦骨基質市場

  • 介紹
  • 醫院
  • 整形外科診所
  • 門診手術中心
  • 其他

9. 各地區去礦骨基質市場

  • 介紹
  • 北美洲
    • 依產品
    • 材料
    • 透過使用
    • 最終用戶
    • 按國家/地區
      • 美國
      • 加拿大
      • 墨西哥
  • 南美洲
    • 依產品
    • 材料
    • 透過使用
    • 最終用戶
    • 按國家/地區
      • 巴西
      • 阿根廷
      • 其他
  • 歐洲
    • 依產品
    • 材料
    • 透過使用
    • 最終用戶
    • 按國家/地區
      • 英國
      • 德國
      • 法國
      • 西班牙
      • 其他
  • 中東和非洲
    • 依產品
    • 材料
    • 透過使用
    • 最終用戶
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 其他
  • 亞太地區
    • 依產品
    • 材料
    • 透過使用
    • 最終用戶
    • 按國家/地區
      • 中國
      • 日本
      • 印度
      • 韓國
      • 台灣
      • 其他

第10章 競爭格局與分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀錶板

第11章 公司簡介

  • Medtronic plc
  • Zimmer Biomet Holdings, Inc.
  • Stryker Corporation
  • DePuy Synthes
  • Exactech, Inc.
  • SeaSpine Holdings Corporation
  • Straumann Group
  • NuVasive, Inc.

第12章附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要收益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061616016

Demineralized Bone Matrix Market is forecasted to grow at a 4.98% CAGR, increasing from USD 1.224 billion in 2025 to USD 1.638 billion in 2031.

The demineralized bone matrix (DBM) market represents a significant segment within the broader orthobiologics and bone graft substitutes industry. DBM is an allograft material processed from human bone to remove its mineral content while retaining osteoinductive proteins and collagenous structure. It functions as a bone void filler and biologic enhancer in skeletal reconstruction, occupying a critical niche between purely osteoconductive synthetics and more complex cellular bone grafts.

Core Product Function and Clinical Rationale

DBM's primary value lies in its osteoinductive potential-the ability to stimulate host stem cells to differentiate into bone-forming osteoblasts. This biological activity, derived from retained bone morphogenetic proteins (BMPs) and growth factors, differentiates it from inert bone graft extenders. Its demineralized, pliable form allows for moldability to fit complex defect geometries. Clinically, DBM is utilized as a graft extender or enhancer in a variety of procedures, most notably spinal fusions, fracture non-unions, and dental/craniomaxillofacial reconstructions, where it supports the natural healing cascade.

Primary Market Growth Drivers

Market expansion is underpinned by a powerful demographic driver: the global aging population. Older adults exhibit a higher prevalence of osteoporosis, degenerative joint disease, and fragility fractures, all of which increase the volume of orthopedic and spinal fusion procedures. This aging demographic ensures a sustained and growing patient base requiring bone grafting solutions to achieve skeletal union, thereby driving consistent demand for DBM as a biologic adjunct.

Parallel to this, the rising incidence of bone-related disorders and trauma, coupled with increasing patient expectations for functional recovery, bolsters procedural volumes. Conditions such as spinal degeneration, non-healing fractures, and significant bone loss following trauma or tumor resection necessitate grafting materials that actively promote healing, supporting the use of osteoinductive agents like DBM.

Technological and processing advancements within the field are key growth vectors. Innovations focus on enhancing the consistency, bioactivity, and handling characteristics of DBM products. This includes improvements in donor screening, processing techniques to preserve growth factor efficacy, and the development of specialized carrier formulations (e.g., gels, putties, strips) that improve surgeon usability and ensure product retention at the surgical site. Research into combining DBM with synthetic scaffolds or other biologics to create optimized composite grafts also represents a forward-looking driver.

The significant and sustained procedural volume within hospital settings, particularly for spinal fusions and complex orthopedic revisions, consolidates DBM's market position. Hospitals serve as the central hub for these surgeries, driven by established surgical protocols, access to supporting technologies (e.g., imaging, navigation), and often favorable reimbursement pathways for allograft-based procedures compared to higher-cost alternatives.

Key Application Segments: Spine and Dental

Two application segments are particularly prominent. The spinal fusion segment represents a core market, where DBM is extensively used as an autograft extender or substitute in posterolateral and interbody fusions to promote arthrodesis. Clinical adoption is supported by its integration into standard surgical workflows for degenerative spine conditions.

The dental application segment is also a major and growing area of use. In oral and maxillofacial surgery, DBM is employed for alveolar ridge preservation, socket grafting following extraction, and sinus lift procedures in preparation for dental implants. Its biologic properties are valued for promoting quality bone regeneration in these sites, and its availability in easy-to-handle forms makes it well-suited for dental surgical practice.

Geographic Landscape and Regional Dynamics

North America maintains a dominant position in the DBM market. This leadership is attributed to a high volume of elective orthopedic and spinal procedures, a well-established tissue banking and allograft processing infrastructure, favorable reimbursement frameworks, and early surgeon adoption of advanced biologic materials. The region's sophisticated healthcare ecosystem supports both supply and demand.

The Asia-Pacific region is identified as a high-growth market with significant expansion potential. This is driven by improving healthcare infrastructure, rising medical tourism, growing adoption of advanced surgical techniques, and increasing healthcare expenditure in populous countries. Government initiatives to modernize medical device regulations and attract foreign investment further stimulate market development and local manufacturing capabilities in the region.

Competitive Landscape and Strategic Focus

The competitive environment includes specialized orthobiologics companies, large orthopedic device firms with biologics divisions, and tissue processing organizations. Competition centers on product portfolio breadth, consistency of osteoinductive potential, carrier technology, and strong surgeon relationships through dedicated sales and medical education teams.

Strategic initiatives are focused on product differentiation through proprietary processing methods, combination products (e.g., DBM with stem cells or synthetic granules), and securing clinical data to support claims of fusion efficacy. Companies also invest in streamlining supply chains from tissue donation to finished product distribution to ensure reliability and scale.

Future Market Trajectory

The future trajectory of the DBM market is oriented toward greater product refinement and evidence-based application. Continued research will aim to better quantify and standardize the osteoinductive potential of different DBM formulations, moving toward more predictable performance. Innovation in delivery systems and combination products will seek to address limitations in handling and retention in challenging surgical sites.

The market will also be influenced by the competitive landscape of bone graft substitutes, including the growth of synthetic alternatives and other advanced biologics. DBM's position will depend on its ability to demonstrate cost-effective biologic augmentation in routine procedures while continuing to serve as a foundational component in complex bone healing scenarios. As a well-established biologic workhorse, DBM is poised for steady growth, reinforced by demographic trends and its entrenched role in the surgical management of bone defects across orthopedic, spinal, and dental specialties.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Demineralized Bone Matrix Market Segmentation

  • By Product
  • Gel
  • Putty
  • Paste
  • Graft
  • Others
  • By Material
  • Human DBM
  • Animal DBM
  • Synthetic DBM
  • By Application
  • Spinal Fusion
  • Dental / Maxillofacial Surgery
  • Trauma Surgery
  • Joint Reconstruction
  • Others
  • By End-User
  • Hospitals
  • Orthopedic Clinics
  • Ambulatory Surgical Centers
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DEMINERALIZED BONE MATRIX MARKET BY PRODUCT

  • 5.1. Introduction
  • 5.2. Gel
  • 5.3. Putty
  • 5.4. Paste
  • 5.5. Graft
  • 5.6. Others

6. DEMINERALIZED BONE MATRIX MARKET BY MATERIAL

  • 6.1. Introduction
  • 6.2. Human DBM
  • 6.3. Animal DBM
  • 6.4. Synthetic DBM

7. DEMINERALIZED BONE MATRIX MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Spinal Fusion
  • 7.3. Dental / Maxillofacial Surgery
  • 7.4. Trauma Surgery
  • 7.5. Joint Reconstruction
  • 7.6. Others

8. DEMINERALIZED BONE MATRIX MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Orthopedic Clinics
  • 8.4. Ambulatory Surgical Centers
  • 8.5. Others

9. DEMINERALIZED BONE MATRIX MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Product
    • 9.2.2. By Material
    • 9.2.3. By Application
    • 9.2.4. By End-User
    • 9.2.5. By Country
      • 9.2.5.1. USA
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. South America
    • 9.3.1. By Product
    • 9.3.2. By Material
    • 9.3.3. By Application
    • 9.3.4. By End-User
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
      • 9.3.5.2. Argentina
      • 9.3.5.3. Others
  • 9.4. Europe
    • 9.4.1. By Product
    • 9.4.2. By Material
    • 9.4.3. By Application
    • 9.4.4. By End-User
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
      • 9.4.5.2. Germany
      • 9.4.5.3. France
      • 9.4.5.4. Spain
      • 9.4.5.5. Others
  • 9.5. Middle East and Africa
    • 9.5.1. By Product
    • 9.5.2. By Material
    • 9.5.3. By Application
    • 9.5.4. By End-User
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
      • 9.5.5.2. UAE
      • 9.5.5.3. Others
  • 9.6. Asia Pacific
    • 9.6.1. By Product
    • 9.6.2. By Material
    • 9.6.3. By Application
    • 9.6.4. By End-User
    • 9.6.5. By Country
      • 9.6.5.1. China
      • 9.6.5.2. Japan
      • 9.6.5.3. India
      • 9.6.5.4. South Korea
      • 9.6.5.5. Taiwan
      • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Medtronic plc
  • 11.2. Zimmer Biomet Holdings, Inc.
  • 11.3. Stryker Corporation
  • 11.4. DePuy Synthes
  • 11.5. Exactech, Inc.
  • 11.6. SeaSpine Holdings Corporation
  • 11.7. Straumann Group
  • 11.8. NuVasive, Inc.

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations